Welcome to our dedicated page for Biovie SEC filings (Ticker: BIVI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioVie Inc.’s SEC disclosures read like a clinical-trial diary—cash runway updates, FDA feedback, and orphan-drug milestones are woven through every 10-K and 10-Q. If you are trying to pinpoint when NE3107 reaches its next Phase 3 data cut-off or how much dilution may come from the latest S-3 shelf, you are in the right place.
Stock Titan’s AI decodes the technical language so you can move straight to decisions. Our platform highlights the exact line items on R&D spending trends, flags fresh BioVie insider trading Form 4 transactions, and summarises BioVie 8-K material events explained within minutes of EDGAR release.
Need fast answers? Search “BioVie quarterly earnings report 10-Q filing” or “BioVie annual report 10-K simplified” and land here: every document, real-time. The AI summary panel shows trial-stage progress, going-concern language, and warrant overhang in plain English. For governance questions, the DEF 14A proxy reveals BioVie proxy statement executive compensation; our tools surface option grants and performance stock units in seconds.
- Real-time alerts on BioVie Form 4 insider transactions
- Side-by-side redlines that compare sequential 10-Q notes
- Concise explanations for complex S-1, S-8 and S-3 capital-raise filings
Whether you are modelling cash burn, tracking BioVie executive stock transactions Form 4, or simply understanding BioVie SEC documents with AI, Stock Titan delivers the context biotech investors need—without wading through 300 pages of pharmacology.
On June 26, 2025, BioVie Inc. filed a Form 8-K announcing that its Board of Directors approved a one-for-ten (1:10) reverse stock split of the Company’s Class A common stock, as previously authorized by shareholders at the June 23, 2025 special meeting. The reverse split will become effective at 12:01 a.m. Eastern Time on July 7, 2025. Each block of ten issued and outstanding shares will automatically be reclassified into one share, with the $0.0001 par value unchanged.
The total number of authorized shares of common stock remains the same. All outstanding stock options, restricted stock units, and warrants will be adjusted proportionally: the number of underlying shares will be divided by ten and the corresponding exercise prices increased by the same factor. No fractional shares will be issued; shareholders otherwise entitled to a fraction will receive one whole post-split share.
West Coast Stock Transfer, Inc. will act as exchange agent, and shareholders holding shares in book-entry or “street name” are not required to take any action. Trading will continue on the Nasdaq Capital Market under the symbol “BIVI” on a split-adjusted basis beginning July 7, 2025. The Company’s common stock will adopt a new CUSIP number: 09074F504.
This event is reported under Item 3.03, constituting a material modification to the rights of security holders.
BioVie held a Special Meeting of stockholders on June 23, 2025, with 10,971,031 shares represented out of 18,570,726 outstanding shares of Class A common stock. Two key proposals were voted on:
Proposal 1: Reverse Stock Split Authorization The stockholders approved granting the Board authority to implement a reverse stock split at a ratio between 1-for-5 and 1-for-10, to be executed within one year. The voting results showed:
- For: 8,664,435 shares (79%)
- Against: 2,200,874 shares
- Abstain: 105,722 shares
Proposal 2: Meeting Adjournment Authority Shareholders approved discretionary authority to adjourn the meeting if needed to gather more proxies, with:
- For: 8,788,143 shares (80%)
- Against: 2,033,834 shares
- Abstain: 149,054 shares
FAQ
What is the current stock price of Biovie (BIVI)?
What is the market cap of Biovie (BIVI)?
What is the core focus of BioVie Inc?
How does BioVie Inc generate its revenue?
What makes BioVie Inc's approach unique compared to other biopharmaceutical companies?
What are the primary drug candidates under development?
How does BioVie Inc ensure the reliability of its clinical data?
What regulatory standards does BioVie Inc adhere to?
Who are the typical stakeholders interested in BioVie Inc?
How does BioVie Inc differentiate its clinical programs?
